[{"source": "https://www.youtube.com/feeds/videos.xml?channel_id=UCF9IOB2TExg3QIBupFtBDxg", "title": "Omicron growth in Norway", "description": "Link to free download of my 2 textbooks http://159.69.48.3/\n\nLouise Restaurant and Bar, night of 26th November\n\nhttps://www.telegraph.co.uk/world-news/2021/12/07/europes-biggest-omicron-outbreak-appears-mild-say-norway-covid/\n\nOslo, Norway, Christmas party\n\nScatec solar power company\n\nOne or two returned traveller\n\nHad returned days earlier\n\n120 people (all double vaccinated)\n\nMingled with outside groups later\n\n70 of the 120 plus 50 others tested positive\n\nHalf tested positive for omicron\n\n13 proven in sequencing\n\nDr. Tine Ravlo, Oslo, infectious diseases\n\nThey have symptoms like fever, cough, headache, muscle pain,  fatigue, \n\nbut for now none of them have become severely ill and none of them have been treated in hospital\n\nThe next day, one of two employees,\n\nrecently returned from South Africa tested positive\n\nNorway's state epidemiologist, Frode Forland\n\nSheer number of people infected at a single event, omicron considerably more infectious than delta\n\nProf Forland, Norwegian Institute of Public Health\n\nOne of three scenarios for omicron,\nit would be both very mild and very transmissible\n\nThat is the hope \nThat is the best scenario we can have\n\nThat it's getting minder, \n\nmost people will get it, \n\nand they will get a natural immunity\n\nIt might be that it has now replicated and mutated so many times,\n\nthat this is the optimal position from the virus' point of view, \n\nto spread widely and not kill the hosts \n\nThat's what we've seen with other diseases beforehand. \n\nAnd of course, then it gets into more like an endemic phase\n\nNow this is not the end\nNor is it the end of the beginning\nRather it is the beginning of the end\n\nSally\nI've had Delta, this time last year (pretty rough, took 6 months to fully recover) and I have Omicron now. The symptoms of Omicron are as you state. I am vaccinated. \n\nHelgard\nLiving in SA (Gauteng) and have tested (+) 2 days ago, The symptoms is 100% correct as stated. Also after 1st symptoms, 3 days after i don't even know that i was sick.\n\nBody and muscle aches and pains\n\nHeadache\n\nTiredness (1 to 2 days)\n\nSlight sore throat\n\nNo severe cough \n\nNo runny nose\n\nGraph refs\n\nhttps://ourworldindata.org/coronavirus\n\nSA. Live data, hospital patients who have tested positive\n\nhttps://www.nicd.ac.za/diseases-a-z-index/disease-index-covid-19/surveillance-reports/daily-hospital-surveillance-datcov-report/\n\nSouth Africa references\n\nhttps://www.nicd.ac.za/diseases-a-z-index/disease-index-covid-19/sars-cov-2-genomic-surveillance-update/\n\nWeekly deaths in SA\n\nhttps://www.samrc.ac.za/reports/report-weekly-deaths-south-africa\n\nVariants in SA\n\nhttps://www.worldometers.info/coronavirus/country/south-africa/\n\nSir Patrick Vallance\n\nfrom pandemic to endemic where this becomes a more regular infection like flu over time\n\nThis virus has mutated a lot, quickly and that is sort of what you would expect at this stage\n\nthe good news is that, so far, it looks as though when you get very high antibody levels with the booster vaccine it's definitely having some effect against it in the laboratory studies\n\nBoris Johnson\n\nWork-from-home from Monday\n\nFacemasks will be enforced in public venues\n\nCovid passes mandatory for nightclubs\n\nDaily testing instead of isolation for omicron contacts\n\nFirst plant-based coronavirus vaccine\n\nCoVLP (20 years of R and D)\n\nhttps://www.gsk.com/en-gb/media/press-releases/medicago-and-gsk-announce-positive-phase-3-efficacy-and-safety-results/\n\nGlaxoSmithKline and Medicago \n\nPrimary endpoints and secondary endpoints met in trial dominated by COVID-19 variants\n\nEfficacy demonstrated against all variants seen in the study, \n\nincluding 75.3% efficacy against COVID-19 of any severity caused by Delta variant\n\nVaccine candidate was well-tolerated, with no related serious adverse events reported in the vaccine group\n\n24,000 adults across six countries\n\nPhase 3 placebo-controlled efficacy study\n\nCanada Medicago\u2019s plant based vaccine\n\nBritish GSK\u2019s pandemic adjuvant\n\nBrian Ward, medical officer at Medicago\n\nplants that are used simply act as bioreactors to produce the antigen\n\nHealth Canada\n\nU.S. Food and Drug Administration\n\nUK, Medicines and Healthcare products Regulatory Agency\n\nWorld Health Organization\n\nWHO \n\nProduced cheaply in very high amounts\n\nCarrier plants such as potatoes and corn\n\nAntigens created are fridge stable and can be stored for long periods of time\n\nthe likelihood that contamination by a plant virus would have an adverse effect on humans is almost negligible\n\nVirus-Like Particles for protein vaccines\n\nCreating empty shells, no RNA\n\nSally\nCan you explain how one variant replaces the other? Does the other variant just fade out?\n\n\n\n\nCampbell's Pathophysiology Notes, Amazon orders for the UK, https://www.amazon.co.uk/dp/B012HWC8SU/ref=cm_sw_em_r_mt_dp_AYC5Q7G3H2B3T4BCHQY0\n\nCampbell's Physiology Notes \nhttps://www.amazon.co.uk/dp/0955379725/ref=cm_sw_em_r_mt_dp_K0MXMAP26Y77TY4J90FB", "link": "https://www.youtube.com/watch?v=5r0AA41dgLU", "date_published": "2021-12-09 00:00:00+00:00", "persistent": false, "user": null, "language": "en-US"}, {"source": "https://www.youtube.com/feeds/videos.xml?channel_id=UCF9IOB2TExg3QIBupFtBDxg", "title": "Intresting interview with Afshin", "description": "Making videos, aspirating before injecting, vitamin D and Omicron. Messages to get out there, thank you Mr. Afshin Rattansi, for taking on the topics often ignored by MSM.\nLink to original video, https://www.youtube.com/watch?v=emG-oMEWlB4", "link": "https://www.youtube.com/watch?v=nkLbZwPoW3E", "date_published": "2021-12-08 00:00:00+00:00", "persistent": false, "user": null, "language": "en-US"}, {"source": "https://www.youtube.com/feeds/videos.xml?channel_id=UCF9IOB2TExg3QIBupFtBDxg", "title": "Omicron, symptom changes", "description": "Link for free download of John's two text books, http://159.69.48.3/\n\nCampbell's Pathophysiology Notes, Amazon orders for the UK, https://www.amazon.co.uk/dp/B012HWC8SU/ref=cm_sw_em_r_mt_dp_AYC5Q7G3H2B3T4BCHQY0\nCampbell's Physiology Notes \nhttps://www.amazon.co.uk/dp/0955379725/ref=cm_sw_em_r_mt_dp_K0MXMAP26Y77TY4J90FB\n\nOmicron, clinical picture (7th December)\n\nDr Angelique Coetzee, South African Medical Association\n\nFirst to raise alarm about the new omicron\n\nhttps://www.youtube.com/watch?v=BtELl7-zE_w\n\nTotally different symptoms\n\nCan be easily missed\n\nBody aches and pains\n\nMuscle pains\n\nHeadache\n\nTiredness (1 to 2 days)\n\nSlight sore throat\n\nNo severe cough \n\nNo runny nose\n\nDecrease in patients coming to doctors\n\nSouth Africa vaccines\n\nPfizer\n\nJ and J\n\nHospitalizations, 99% unvaccinated\n\nSymptoms more intense in unvaccinated\n\nMore intense but not severe\n\nBody aches and pains\n\nMuscle pains\n\nHeadache\n\nLateral flow testing and Omicron\n\nBecomes positive after 24 hours up to 5 days\n\nVery accurate\n\nOmicron prevalence in SA\n\nhttps://www.nicd.ac.za\n\nRef for graphics (3rd December data)\n\nhttps://www.nicd.ac.za/wp-content/uploads/2021/12/Update-of-SA-sequencing-data-from-GISAID-3-Dec-21-Final.pdf\n\nSGTF has increased from 0.9% in October to 96.3% for November. \n\nChildren under the age of 12 years accounted for 7.9% of the SGTF positives,\n\nand those 13 \u2013 18 years old for 6.1%.\n\nFor week 47, \n\nHospital data from SA\n\nhttps://www.nicd.ac.za/wp-content/uploads/2021/12/NICD-COVID-19-Daily-Sentinel-Hospital-Surveillance-report-National-20211206.pdf\n\nLive data, hospital patients who have tested positive\n\nhttps://www.nicd.ac.za/diseases-a-z-index/disease-index-covid-19/surveillance-reports/daily-hospital-surveillance-datcov-report/\n\nOmicron and common cold\n\nhttps://osf.io/f7txy/\n\nOmicron has insertion mutation ins214EPE\n\n(From the common cold, HCoV-229E coronavirus)\n\nCould have been acquired by switching\n\nInvolving the genomes of other viruses that infect the same host cells as SARS-CoV-2\n\nIt is plausible that the Omicron insertion\ncould have evolved in a co-infected individual\n\nPFIZER AND BIONTECH PROVIDE UPDATE ON OMICRON VARIANT\n\nhttps://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-provide-update-omicron-variant\n\nPreliminary laboratory studies demonstrate that three doses of the Pfizer-BioNTech COVID-19 Vaccine neutralize the Omicron variant (B.1.1.529 lineage),\n\nwhile two doses show significantly reduced neutralization titers\n\nData indicate that a third dose of BNT162b2 increases the neutralizing antibody titers by 25-fold compared to two doses against the Omicron variant;\n \ntiters after the booster dose are comparable to titers observed after two doses against the wild-type virus which are associated with high levels of protection\n\nAs 80% of epitopes in the spike protein recognized by CD8+ T cells are not affected by the mutations in the Omicron variant, two doses may still induce protection against severe disease\n\nThe companies continue to advance the development of a variant-specific vaccine for Omicron and expect to have it available by March\n\nin the event that an adaption is needed to further increase the level and duration of protection \u2013 with no change expected to the companies\u2019 four billion dose capacity for 2022", "link": "https://www.youtube.com/watch?v=5E6gpPJwYIY", "date_published": "2021-12-08 00:00:00+00:00", "persistent": false, "user": null, "language": "en-US"}]